If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, the 2 main omega-3 long-chain polyunsaturated fatty acids of marine origin, have shown promise for the prevention of cardiovascular disease (CVD) outcomes in animal studies and epidemiologic studies.
on the subject. The authors observe that the results of these new trials (Outcomes Study to Assess Statin Residual Risk Reduction With EpaNova in High CV Risk Patients With Hypertriglyceridemia [STRENGTH]
) need to be examined in the context of existing research. In particular, they suggest that it is necessary to update the results and review the conclusions of our meta-analysis.
Following their suggestion, with the addition of these new trials (both of which meet our inclusion criteria), our analysis now covers 42 studies with a combined 149,359 participants. As only results for CVD and coronary heart disease (CHD) outcomes were made available in the 2 new trials, our original results
for myocardial infarction (MI) relative risk (RR), 0.87; 95% confidence interval [CI], 0.80 to 0.96, high GRADE certainty, fatal MI RR, 0.65; 95% CI, 0.46 to 0.91, moderate certainty and CHD mortality RR, 0.91; 95% CI, 0.85 to 0.98, low certainty remain unchanged.
The newly published results change slightly the meta-analysis estimates, but not the conclusions, for CVD events and CHD events. For CVD events, the pooled estimate is now RR, 0.96; 95% CI, 0.91 to 1.00 (changed from RR, 0.95; 95% CI, 0.90 to 1.00). For CHD events: RR, 0.91; 95% CI, 0.85 to 0.97 (changed from RR, 0.90; 95% CI, 0.84 to 0.97). These results are summarized in the Figure.
The effect remains dose dependent for MI; an additional 1 g/d in EPA and DHA is associated with a 9% reduction in MI but no longer for CVD events. None of the other conclusions is changed; the effect remains independent of the year of publication, the population baseline risk, or whether the long-chain polyunsaturated fatty acids agent consisted of only EPA or a combination of EPA and DHA.
Although we believe that understanding why a high-dosage trial, such as STRENGTH, failed to find an effect will require more research, the totality of the evidence, including now 42 studies involving almost 150,000 participants, shows statistically significant reductions in fatal MI (–35%), MI (–13%), CHD events, and CHD mortality (both –9%). This is still consistent with the conclusion that EPA and DHA intake is an effective lifestyle intervention for protection against CVD.
Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.
Potential Competing Interests: Dr Bernasconi is an employee of the Global Organization for EPA and DHA Omega-3s (GOED), a 501(c)6 not-for-profit trade association. Dr Lavie has served as speaker for Amarin Corporation, has consulted for DSM Nutritional Products, and has presented an educational video at the American Heart Association meeting for GOED. The other authors report no competing interests.